Effectiveness of Corticosteroid Monotherapy for Dyspnea Relief in Patients with Terminal Cancer.

Abstract

Dyspnea is a common symptom in patients with cancer, particularly those with late-stage terminal disease. It markedly affects terminal cancer patients, reducing their quality of life. Reduced quality of life also affects survival; therefore, dyspnea is a prognostic factor. However, the role of corticosteroids, which often are used to alleviate dyspnea, has not been sufficiently validated. In this study, we retrospectively investigated whether corticosteroid monotherapy was effective for dyspnea palliation. The effectiveness rate of corticosteroid therapy was 45% in nine male and two female study subjects (mean age: 74.5 years; range: 64-86 years). No significant differences were found between responders and nonresponders in the first-day corticosteroid doses (25.5 ± 10.86 vs. 36.1 ± 16.39 mg, P = .29) or doses administered on 2 days (47.7 ± 25.99 vs. 72.2 ± 32.78 mg, P = .25). The mean ± standard error assessment score changed significantly from 2.7 ± 0.14 at the beginning of corticosteroid administration to 1.5 ± 0.37 at the time of maximum effect (P = .028); however, the decrease to 2.1 ± 0.25 at the final administration was not significant (P = .068). This indicates that corticosteroid therapy relieved dyspnea and could provide an early-stage treatment option.

• Authors: Tsuyoshi Maeda, Toru Hayakawa
• Journal: Journal of pain & palliative care pharmacotherapy (J Pain Palliat Care Pharmacother) Vol. 31 Issue 2 Pg. 148-153 (Jun 2017) ISSN: 1536-0539 [Electronic] England
• PMID: 28358257 (Publication Type: Journal Article)

Chemical References

• Adrenal Cortex Hormones

Topics

• Adrenal Cortex Hormones (therapeutic use)
• Aged
• Aged, 80 and over
• Dyspnea (complications, drug therapy)
• Female
• Humans
• Male
• Middle Aged
• Neoplasms (complications, drug therapy)
• Palliative Care
• Retrospective Studies